Business Context and Reporting Period
This Form 8-K was filed by CalciMedica, Inc. on August 11, 2023. The report serves to update the Company's business description and provide recasted financial statements following a merger transaction completed on March 20, 2023. In this transaction, Graybug Vision, Inc. merged with Private CalciMedica, and the surviving entity changed its name to CalciMedica, Inc. The Company is an emerging growth company.
Key Financial Metrics
This filing does not contain current period revenue, profit, cash flow, or liquidity metrics. The document focuses on the structural changes resulting from the merger. It references audited recasted financial statements for Private CalciMedica for the years ended December 31, 2022, and 2021, which are attached as Exhibit 99.2, but specific numerical values for these periods are not included in the text of this report.
Material Changes
- Merger Completion: On March 20, 2023, Graybug Vision, Inc. merged with Private CalciMedica. Private CalciMedica survived as a wholly owned subsidiary.
- Name Change: The Company's name was changed from "Graybug Vision, Inc." to "CalciMedica, Inc."
- Reverse Stock Split: A 14:1 reverse stock split of Graybug's common stock was effected on March 17, 2023.
- Exchange Ratio: Common stock was issued to Private CalciMedica stockholders at an exchange ratio of approximately 0.0288 shares for each share of Private CalciMedica capital stock.
- Financial Recasting: Historical financial statements of Private CalciMedica have been recasted to reflect the exchange ratio.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements related to the Company's business strategy, the development of its product candidate Auxora, and clinical trial programs (CARPO and CRSPA). Management notes that actual results may differ materially due to various risks, including:
- Regulatory approval uncertainties for Auxora.
- Clinical trial outcomes and safety complications.
- Market acceptance and competitive factors.
- Intellectual property protection.
- Global financial market fluctuations.
The Company assumes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.2 for the specific recasted audited financial statements of Private CalciMedica for 2021 and 2022.
- Verify the updated business description in Exhibit 99.1.
- Consult the most recent Form 10-Q (for the quarter ended June 30, 2023) for detailed risk factors and current liquidity status.
- Monitor upcoming data announcements and enrollment milestones for the CARPO and CRSPA clinical trials.